Loading...
XNAS
CLNNW
Market cap37mUSD
Jun 05, Last price  
0.03USD
1D
-19.55%
1Q
-19.14%
IPO
-96.79%
Name

Clene Inc.

Chart & Performance

D1W1MN
P/E
P/S
109.92
EPS
Div Yield, %
Shrs. gr., 5y
-16.86%
Rev. gr., 5y
%
Revenues
342k
-47.71%
000206,000723,000473,000654,000342,000
Net income
-39m
L-20.41%
0-277,311-16,270,000-19,277,000-9,740,000-15,279,000-49,504,000-39,400,000
CFO
-21m
L-29.32%
-205,372-13,197,000-18,929,000-34,624,000-39,011,000-30,171,000-21,326,000
Earnings
Aug 05, 2025

Profile

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
IPO date
Aug 27, 2018
Employees
75
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
342
-47.71%
654
38.27%
473
-34.58%
Cost of revenue
33,435
41,194
48,882
Unusual Expense (Income)
NOPBT
(33,093)
(40,540)
(48,409)
NOPBT Margin
Operating Taxes
(14,639)
Tax Rate
NOPAT
(33,093)
(40,540)
(33,770)
Net income
(39,400)
-20.41%
(49,504)
224.00%
(15,279)
56.87%
Dividends
Dividend yield
Proceeds from repurchase of equity
9,243
42,094
11,460
BB yield
Debt
Debt current
1,285
20,709
6,980
Long-term debt
24,616
17,561
30,997
Deferred revenue
Other long-term liabilities
6,345
1,566
2,555
Net debt
13,746
3,270
14,662
Cash flow
Cash from operating activities
(21,326)
(30,171)
(39,011)
CAPEX
(15)
(330)
(5,179)
Cash from investing activities
6,316
(1,499)
(10,164)
Cash from financing activities
(1,529)
42,163
17,249
FCF
(30,784)
(38,731)
(40,588)
Balance
Cash
12,155
35,000
23,315
Long term investments
Excess cash
12,138
34,967
23,291
Stockholders' equity
(282,051)
(242,511)
(193,009)
Invested Capital
300,382
290,231
230,625
ROIC
ROCE
EV
Common stock shares outstanding
6,954
5,247
65,205
Price
Market cap
EV
EBITDA
(31,448)
(38,835)
(47,390)
EV/EBITDA
Interest
4,064
4,558
3,296
Interest/NOPBT